Makers Laboratories
- Market cap
- ₹ 113 Cr.
- P/E
- 33.2x
- P/B
- 1.61x
- 52-week range
- 150 – 236
- ROE
- 3%
- ROCE
- 9%
- Dividend yield
- 0%
- Debt / equity
- 0.08
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Makers Laboratories Limited is an integrated pharmaceutical company manufacturing and marketing around 200 formulations. The Company's segments include Pharmaceutical and Chemical Manufacturing. It has one manufacturing unit in India manufacturing formulations for the Indian market. Its product portfolio covers a range of general health therapeutic segments. Its formulation brands are Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimesulide), Coffwin (Anti-Cough range) and Exylin (Amoxycillin range). It also offers a range of diabetic and hypertensive drugs, including Voglibose, Gli-me range (Glimepiride + Metformin +Pioglitazone), and Hypernorm range (Telmisartan). Its product categories include Inspira - Retail Packs and Experia - Bulk Packs. Its Inspira - Retail Packs include anthelmintics, anti-biotics, anti-emetics and anti-nauseants. Its Experia - Bulk Packs include betamethasone 0.5 mg tablets, chloramphenicol capsules 250 mg and diclofenac 50 mg tablets.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Makers Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)33.2 against a typical 34: cheaper than most peers (1st = cheapest).108th of 220
- Sales growth+22.2% against a typical +15.6% from a year earlier.73rd of 197
- Profit growth+255.8% against a typical +18.9% from a year earlier.15th of 160
- Size₹ 113.3 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).143rd of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB+ by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE BBB+ | Stable | 4 Sep 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 4 Sep 2026 | Reaffirmed | CARE BBB+ | — | CARE | ₹ 4 Cr. | |
| 3 Sep 2025 | Withdrawn | was CARE BBB+ | — | CARE | ₹ 8 Cr. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 27 | 28 | 30 | 30 | 28 | 34 | 35 | 34 | 36 | 36 | 43 |
| Expenses | 25 | 26 | 27 | 28 | 27 | 26 | 31 | 32 | 32 | 32 | 30 | 36 |
| Operating Profit | 0 | 0 | 1 | 2 | 2 | 1 | 3 | 3 | 2 | 4 | 5 | 7 |
| OPM % | 0.8% | 0.8% | 3.1% | 6.1% | 7.4% | 4.7% | 9.1% | 8.6% | 6.7% | 11.7% | 14.8% | 16.3% |
| Other Income | 0 | 0 | 0 | −1 | 11 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Interest | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | −1 | −1 | −0 | −0 | 11 | 1 | 2 | 2 | 1 | 3 | 5 | 6 |
| Tax % | 10.9% | −4.5% | 152.6% | 48.9% | 12% | 60.3% | 24.6% | 34.9% | 42.6% | 27.9% | 24.9% | 27% |
| Net Profit | −1 | −1 | −1 | −1 | 10 | 0 | 2 | 1 | 1 | 2 | 4 | 5 |
| EPS in Rs | −2.27 | −2.61 | −2.19 | −1.66 | 14.95 | −0.51 | −0.08 | 0.75 | −0.2 | 1.59 | 1.85 | 2.54 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 15%
- 3 Years
- 12%
- TTM
- 18%
- 10 Years
- —
- 5 Years
- 49%
- 3 Years
- 35%
- TTM
- −61%
- 10 Years
- 11%
- 5 Years
- −2%
- 3 Years
- 16%
- TTM
- —
- 10 Years
- —
- 5 Years
- −1%
- 3 Years
- −2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Makers Laboratories | ₹ 190.50 | ₹ 113 Cr. | 33.2x | 1.6x | 3% | — |
| Aurobindo Pharma | ₹ 1,569.30 | ₹ 90,294 Cr. | 25.1x | 2.4x | 9.9% | 10.4% |
| Neuland Laboratories | ₹ 18,882.05 | ₹ 24,132 Cr. | 64.3x | 12.6x | 21.4% | 18% |
| Pfizer | ₹ 3,610.35 | ₹ 16,513 Cr. | 27.5x | 5x | 17.2% | 28.7% |
| Unichem Laboratories | ₹ 470.00 | ₹ 3,309 Cr. | 54.3x | 1.5x | 9.8% | 11.5% |
| Jagsonpal Pharmaceuticals | ₹ 213.00 | ₹ 1,402 Cr. | 34.3x | 5.4x | 16.7% | 15% |
Management
- Saahil Parikh
- Chief Executive Officer, Whole-Time Director
- Sandeep Kadam
- Manager - Accounts, Chief Financial Officer
- Piyush Ajmera
- Compliance Officer, Company Secretary
- Nilesh Jain
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.